Vital Health Podcast: Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation

Vital Health Podcast: Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation

Listen to Erik Tambuyzer, PhD (Chairperson of BioPontis Alliance for Rare Diseases) discuss his pioneering work in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics. As an entrepreneur in 1985, he had co-founded and managed the biotech company Innogenetics, ultimately acquired by Fujirebio. He is the Executive Chairperson and co-founder of the BioPontis Alliance for Rare Diseases, an international philanthropic foundation turning science into medicines.

This Better Science, Better Health Podcast is made possible with the support of EUCOPE.


About BioPontis Alliance for Rare Diseases

BioPontis Alliance for Rare Diseases is a 501c(3) public charity in the US (North Carolina) and a foundation of public utility (fup/son) in Belgium (Brussels). Managed by an international Board and executive team, BioPontis partners with patient organizations and clinical researchers to bridge the gap between promising science and new medicines. BioPontis Alliance for Rare Diseases is being established as a global non-profit, inviting corporate, private and foundation philanthropic support. More information, including how contributions to support our programs and mission can be made, at http://biopontisalliance.org.

Contacts:

David Spencer, PhD – CSO
BioPontis Alliance for Rare Diseases
+1.919.624.0841 (Raleigh, USA)
dspencer@biopontisalliance.org

Erik Tambuyzer, PhD – Chairperson
BioPontis Alliance for Rare Diseases
+32 475 61 57 11 (Brussels, Belgium)
Erik.Tambuyzer@biopontisalliance.org